Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA

CompletedOBSERVATIONAL
Enrollment

140

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

July 30, 2024

Study Completion Date

September 6, 2024

Conditions
Transplant;Failure,KidneyTransplant; Failure, PancreasRejection Acute RenalRejection Acute Pancreas
Interventions
DIAGNOSTIC_TEST

dd-cfDNA Blood Test

The cfDNA measurement isolated from the peripheral blood contains small amounts from the graft. The blood sample is collected in Cell-Free DNA BCT (blood collection) tubes. These are measured by their difference in SNP (single nucleotide polymorphisms) genotype to determine the ratio of donor to recipient through shotgun sequencing. Higher levels of dd-cfDNA in a patient experiencing rejection is measured as a higher percentage of the total cf-DNA.

Trial Locations (3)

20007

Georgetown University, Washington D.C.

21201

University of Maryland, Baltimore

53792

UW Health University Hospital, Madison

All Listed Sponsors
collaborator

University of Wisconsin, Madison

OTHER

collaborator

Georgetown University

OTHER

lead

University of Maryland, Baltimore

OTHER

NCT04166149 - Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA | Biotech Hunter | Biotech Hunter